These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. HIV-1 gp41: mediator of fusion and target for inhibition. Weiss CD AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000 [TBL] [Abstract][Full Text] [Related]
3. HIV fusion and its inhibition. LaBranche CC; Galasso G; Moore JP; Bolognesi DP; Hirsch MS; Hammer SM Antiviral Res; 2001 May; 50(2):95-115. PubMed ID: 11369431 [No Abstract] [Full Text] [Related]
7. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41. Jiang S; Debnath AK Biochem Biophys Res Commun; 2000 Mar; 269(3):641-6. PubMed ID: 10720469 [TBL] [Abstract][Full Text] [Related]
8. Unwelcome guests with master keys: how HIV enters cells and how it can be stopped. Doms RW Top HIV Med; 2004; 12(4):100-3. PubMed ID: 15516706 [TBL] [Abstract][Full Text] [Related]
9. [1,2,6-tri-O-galloyl-beta-D-glucopyranose inhibits gp41-mediated HIV envelope fusion with target cell membrane]. Sun W; Wang HT; Xia CL; Wu SG; Jiang SB; Jiang ZH; Liu SW Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1127-31. PubMed ID: 18676243 [TBL] [Abstract][Full Text] [Related]
10. Hexapeptides that interfere with HIV-1 fusion peptide activity in liposomes block GP41-mediated membrane fusion. Gómara MJ; Lorizate M; Huarte N; Mingarro I; Perez-Payá E; Nieva JL FEBS Lett; 2006 May; 580(11):2561-6. PubMed ID: 16647705 [TBL] [Abstract][Full Text] [Related]
11. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. Jiang S; Debnath AK Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920 [TBL] [Abstract][Full Text] [Related]
12. The world of HIV and disease, and some new approaches to block it. Gallo R Bull Mem Acad R Med Belg; 1998; 153(7-9):339-42. PubMed ID: 10100397 [No Abstract] [Full Text] [Related]
13. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053 [TBL] [Abstract][Full Text] [Related]
14. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV. Gustchina E; Hummer G; Bewley CA; Clore GM J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842 [TBL] [Abstract][Full Text] [Related]
15. New anti-HIV agents and targets. De Clercq E Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088 [TBL] [Abstract][Full Text] [Related]
16. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4. Kazmierski WM; Kenakin TP; Gudmundsson KS Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145 [TBL] [Abstract][Full Text] [Related]
17. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018 [TBL] [Abstract][Full Text] [Related]
18. Inhibitors of the entry of HIV into host cells. Meanwell NA; Kadow JF Curr Opin Drug Discov Devel; 2003 Jul; 6(4):451-61. PubMed ID: 12951808 [TBL] [Abstract][Full Text] [Related]
19. Identification of peptide ligands to the chemokine receptor CCR5 and their maturation by gene shuffling. Vyroubalova EC; Hartley O; Mermod N; Fisch I Mol Immunol; 2006 Apr; 43(10):1573-8. PubMed ID: 16280164 [TBL] [Abstract][Full Text] [Related]
20. Anti-HIV agents. Can valproic acid help flush HIV from hiding? TreatmentUpdate; 2005; 17(6):4-5. PubMed ID: 17228475 [No Abstract] [Full Text] [Related] [Next] [New Search]